Business Wire

New data support the use of LIXIANA® (edoxaban) in complex patient populations with atrial fibrillation (AF)


Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced a wealth of new edoxaban data being presented at ESC Congress 2021, organised by the European Society of Cardiology. These include insights from routine clinical practice via the ETNA-AF Registry, which reaffirm the efficacy and safety profile of edoxaban seen in randomised clinical trials across a range of atrial fibrillation (AF) patient populations. In addition, results from the ENVISAGE-TAVI AF study, presented as a Hot Line session during the congress, compared the efficacy and safety of edoxaban with vitamin-K-antagonists (VKA) in patients with AF having undergone successful transcatheter aortic valve implantation (TAVI).1 Findings from the trial were simultaneously published in The New England Journal of Medicine (NEJM).

The revised 2021 EHRA* Practical Guide on the Use of NOACsin Patients with Atrial Fibrillation (AF), which was published earlier this year (April), recommends the use of NOACs as first-line treatment of patients with AF and includes specific guidance around treating complex AF patient populations, such as those with different levels of frailty and those with renal impairment.2 The data presented today further complement the recommendations of the Practical Guide for the treatment of AF patients using NOACs.

“These new data, in addition to the recently updated EHRA Practical Guide on the use of NOACs in AF, provide long-awaited scientific evidence that the clinical community will welcome as a huge support in helping treat these complex patient populations with AF,” said Prof. Hein Heidbuchel, Chair of Cardiology at Antwerp University, Belgium, and immediate Past-President of the European Heart Rhythm Association (EHRA). “It is acknowledged across the world now that NOACs are the preferred choice of treatment for patients with AF. Having additional data to help guide healthcare professionals in the specifics of anticoagulating these patient populations will bring further clarity and confidence to the clinical community.”

ETNA-AF-Europe Registry: Worsening renal function (WRF) and frailty

Key ePosters presented from the ETNA-AF-Europe Registry include the evaluation of the degree of worsening renal function (WRF) in AF patients treated with edoxaban after two-years of follow-up and an investigation of clinical outcomes of patients with vs. without WRF. Results from 9,084 patients included in this subgroup analysis showed that there is a low risk of WRF in AF patients treated with edoxaban over a two-year period, with the majority of the edoxaban-treated patients not experiencing WRF (89.9%). Results also found that:3

  • Patients with WRF had higher mortality than those without (all-cause mortality: 3.78% vs. 1.90%; cardiovascular death: 2.06% vs. 0.92%, respectively).
  • Patients with WRF had numerically higher major bleeding and stroke rates vs. those without WRF.
  • Importantly, intracranial haemorrhage rates remained low irrespective of WRF (0.17% in those with WRF vs. 0.19% in those without).

A second key ePoster analysed effectiveness and safety outcomes in subjectively vs. objectively frail patients in the overall population. Results showed that the presence of frailty (either subjective or objective) predicts cardiovascular (CV) events in anticoagulated patients with AF and is associated with a worse prognosis of CV events.4 These results support the idea that a comprehensive assessment of frailty could improve the routine care of patients with AF and are in line with the ESC 2020 guidelines, which highlight the importance of including assessment and evaluation of frailty into the integrated management of AF.5


In addition, results from the ENVISAGE-TAVI AF study were presented as a Hot Line session during the ESC congress 2021. In this multinational, randomised, Phase 3b study, 1,426 elderly patients with multiple comorbidities were included and followed for up to three years.1,6 The study results suggest that edoxaban is an appropriate treatment option for AF patients with severe aortic stenosis following successful TAVI.1,6 To date, this is the only sufficiently large and statistically powered study that compares a non-vitamin K antagonist oral anticoagulant (NOAC) with VKAs in AF patients after TAVI.1,6

“TAVI is an established treatment option for patients with severe aortic valve stenosis, including those with AF and multiple comorbidities,” said George Dangas, MD, PhD, Professor of Medicine (Cardiology) and Director of Cardiovascular Innovation at the Zena and Michael A. Wiener Cardiovascular Institute at the Icahn School of Medicine at Mount Sinai. “In AF patients, anticoagulation is required to prevent stroke, which can be a devastating complication following TAVI. ENVISAGE-TAVI AF shows that treatment with edoxaban can be valuable in the management of this high-risk population of AF patients after TAVI.”

The study met its primary endpoint of edoxaban being noninferior to VKAs for the composite of net adverse clinical events (NACE), which included all-cause mortality, myocardial infarction, ischaemic stroke, systemic thromboembolism, valve thrombosis, and International Society on Thrombosis and Haemostasis (ISTH)-defined major bleeding.1,6 NACE occurred in 170 edoxaban-treated patients (17.3% per year) and, similarly, in 157 VKA-treated patients (16.5% per year).1,6

Edoxaban also showed numerically lower rates of all-cause mortality and ischemic stroke (two of the six individual clinical events included in the composite of NACE):1,6

  • All-cause mortality occurred in 85 edoxaban-treated patients and 93 VKA-treated patients (7.8% versus 9.1% per year, respectively).
  • Ischaemic stroke occurred in 22 edoxaban-treated patients and 28 VKA-treated patients (2.1% versus 2.8% per year, respectively).

The study did not meet its primary safety endpoint of ISTH-defined major bleeding, due to more gastrointestinal (GI) bleeds in the edoxaban arm.1,6 Other major bleeding events, including intracranial haemorrhage (ICH), as well as fatal and life-threatening bleeds, were similarly rare in both the edoxaban and VKA treatment arms.1,6

Major bleeding occurred in 98 edoxaban-treated patients and 68 VKA-treated patients (9.7% vs. 7.0% per year, respectively), which included the following:1,6

  • Major GI bleeding occurred in 56 edoxaban-treated patients and 27 VKA-treated patients (5.4% vs. 2.7% per year, respectively).
  • ICH occurred in 16 edoxaban-treated patients and 21 VKA-treated patients (1.5% vs. 2.1% per year, respectively).
  • Fatal bleeding occurred in 11 edoxaban-treated patients and 10 VKA-treated patients (1.0% vs. 1.0% per year, respectively).
  • Life threatening bleeding occurred in 17 edoxaban-treated patients and 19 VKA-treated patients (1.6% vs. 1.9% per year, respectively).

“These findings present evidence that edoxaban is an appropriate treatment option in AF patients post-TAVI, who are typically elderly and frail,” said Prof. Nicolas Van Mieghem, global co-lead investigator from Erasmus University Medical Center in Rotterdam, The Netherlands. “We found more major bleedings with edoxaban driven by more gastrointestinal bleedings that were well managed with no significant difference in intracranial or fatal bleedings.”

ETNA-AF-Europe and the ENVISAGE TAVI-AF study are part of EDOSURE, which is an extensive clinical research programme for edoxaban consisting of more than 10 randomised controlled trials, registries and non-interventional studies in a broad range of cardiovascular conditions, patient types and clinical settings in AF and venous thromboembolism (VTE), involving over 100,000 patients worldwide.

Additional edoxaban data presented at ESC Congress 2021


Age-adjusted risk factors are independently associated with an increased risk of ischaemic stroke, transient ischaemic stroke and systemic embolism in the ETNA-AF-Europe registry (link to data here)

De Caterina R, et al.



Age-adjusted risk factors are independently associated with an increased risk of major bleeding during the two-year follow-up of the ETNA-AF-Europe registry (link to data here)

Kirchhof P, et al.


Global ETNA-AF

Temporal trend of clinical events in patients with atrial fibrillation on edoxaban therapy: Results from the noninterventional Global ETNA-AF program (link to data here)

Dinshaw L, et al.



Edoxaban treatment in real-world practice is highly concordant with ESC atrial fibrillation guidelines: results from the non-interventional global ETNA-AF program (link to data here)

Morrone D, et al.



Effectiveness and safety of edoxaban in atrial fibrillation patients from the ETNA-AF global registry (link to data here)

De Caterina R, et al.



Impact of polypharmacy on clinical outcomes in elderly patients with nonvalvular atrial fibrillation: sub-analysis of the ANAFIE Registry (link to data here)

Yamashita T.



Predictors for major bleeding in elderly (75 years and over) patients with nonvalvular atrial fibrillation at high risk of bleeding: sub-analysis of the ANAFIE Registry (link to data here)

Okumura K.



Association between renal function and clinical outcomes in elderly patients with nonvalvular atrial fibrillation: sub-analysis of the ANAFIE Registry (link to data here)

Shimizu W.



Real-world clinical outcomes and anticoagulant therapy in elderly non-valvular atrial fibrillation patients with heart failure: sub-analysis of the ANAFIE Registry (link to data here)

Ikeda S, Hiasa K, Tsutsui H.



Epistaxis in anticoagulated patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial (link to data here)

Semco RS, et al.


About ETNA-AF:


About atrial fibrillation:

About edoxaban:

About the Edoxaban Clinical Research Programme, EDOSURE:

About Daiichi Sankyo

Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realise our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.”

For more information, please visit

Forward-looking statements:


* European Heart Rhythm Association
† Non-Vitamin K Antagonist Oral Anticoagulants

1 Dangas G. ENVISAGE-TAVI AF: edoxaban vs. vitamin K antagonists after TAVI in patients with atrial fibrillation. Hot Line Presentation at ESC Congress 2021, 27–30 August.
2 Steffel J, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. EP Europace. 2021; euab065, .
3 Gwechenberger M, et al. Low rate of worsening renal function during 2 years of treatment with edoxaban in patients from the ETNA-AF-Europe study. Poster 84715. Presented at ESC Congress 2021.
4 Diemberger I, et al. The impact of subjective vs objective frailty on the effectiveness and safety outcomes in patients from ETNA-AF-Europe registry. Poster 84668. Presented at ESC Congress 2021.
5 Hindricks G, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42:373–498.
6 Van Mieghem NM, et al. Edoxaban vs Vitamin K Antagonist for Atrial Fibrillation After Transcatheter Aortic Valve Replacement. N Engl J Med. 2021. Available at: Last accessed August 2021.

To view this piece of content from, please give your consent at the top of this page.

Contact information

Dr. Wolfgang Schiessl
Daiichi Sankyo Europe GmbH
Director PR and Portfolio Communications, Specialty Medicines
+49 151 1714 7317

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Spirit of Wipro Run Brings Together Participants From Over 35 Countries26.9.2021 15:57:00 EEST | Press release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today organized the 16th annual ‘Spirit of Wipro’ (SOW) Run, drawing thousands of participants from over 35 countries to run together in spirit. For the past sixteen years, Wiproites around the world have come together to celebrate Wipro’s core values. The annual SOW run aims to inspire employees to be responsible citizens of the world. This year’s theme was “Together. To greatness,” inspired by the resilience demonstrated by Wiproites in a year of unprecedented disruption. Along with outperforming across all business parameters, Wipro teams have remained committed to supporting their colleagues and creating a lasting social impact across communities. Like last year, this year’s race was also virtual, and runners strictly adhered to the local COVID-19 guidelines and safety protocols while participating in the event. Even under these conditions,

Pencil Lab Inks Debut in ADIHEX 202125.9.2021 13:04:00 EEST | Press release

The 18th edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) on September 27 - October 3 marks an opportune platform for Pencil Lab Design Studio’s first major participation in the massive event, the largest of its kind in the Middle East and Africa. This press release features multimedia. View the full release here: Pencil Lab Inks Debut in ADIHEX 2021 (Photo: AETOSWire) Featuring more than 800 brands and companies, the event is held under the theme of ‘Sustainability and Heritage… A Reborn Aspiration’, highlighting heritage, culture and authentic sports and their strong relation with Arab history. As part of its inaugural participation in a major exhibition as a company, Pencil Lab, a UAE initiative, will showcase their artworks with three large oil paintings by Pencil Lab’s citizen artist, to highlight the strong connection of arts, like painting and photography, to Arab history and civilization.

DXC Technology Completes Refinancing Actions24.9.2021 23:30:00 EEST | Press release

DXC Technology Company (NYSE: DXC) (“DXC”) today announced the completion of its refinancing. DXC previously completed the offering of €1.35 billion Senior Notes priced on September 2, 2021 and $1.35 billion Senior Notes priced on September 7, 2021. DXC completed redemption of $2.5 billion principal of (i) EUR term loan in the amount of €400 million due FY23 and FY24, (ii) $500 million 4.25% Senior notes due FY25, (iii) £250 million 2.75% Senior notes due FY25, (iv) $467 million 4.125% Senior notes due FY26, (v) $500 million 4.75% Senior notes due FY28, and (vi) $234 million Senior notes due FY30. The applicable make whole premium for these redemptions was $300 million and accrued and unpaid interest was $40 million. Ken Sharp, Chief Financial Officer, DXC commented: “Our opportunistic debt refinancing of $2.5 billion of our high coupon debt further solidifies our financial foundation by extending our debt maturities, lowering our maturity towers and reducing our ongoing interest expen

Schlumberger Announces Third-Quarter 2021 Results Conference Call24.9.2021 17:00:00 EEST | Press release

Schlumberger Limited (NYSE:SLB) will hold a conference call on October 22, 2021 to discuss the results for the third quarter ending September 30, 2021. The conference call is scheduled to begin at 9:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (844) 721-7241 within North America or +1 (409) 207-6955 outside of North America approximately 10 minutes prior to the start of the call and the access code is 8858313. A webcast of the conference call will be broadcast simultaneously at on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at until November 22, 2021, and can be accessed by dialing +1 (866) 207-1041 within North America or +1 (402

Tradeweb Successfully Completes its First Southbound Bond Connect Transactions24.9.2021 15:07:00 EEST | Press release

Tradeweb Markets Inc. (Nasdaq: TW), a leading global operator of electronic marketplaces for rates, credit, equities and money markets, today announced it has completed its first Southbound Bond Connect transactions via the trading link between Tradeweb and China Foreign Exchange Trade System (CFETS). “Southbound Bond Connect is the latest evolutionary step for China’s financial market, providing domestic investors with more flexibility and choice when trading offshore bonds,” said Lee Olesky, CEO of Tradeweb Markets. “Together with CFETS, our goal is to better meet onshore investors’ demand for streamlined access to global investment. We will continue to focus on further enhancing the trading link by deploying new innovative trading functionality, just as we did with the Northbound leg of Bond Connect.” Southbound Bond Connect facilitates fixed income portfolio diversification for institutional investors in China. Tradeweb collaborates closely with CFETS to create a uniform trading ex

H.I.G. Capital Acquires Aspire Pharma24.9.2021 15:05:00 EEST | Press release

H.I.G. Capital, LLC (“H.I.G.”), a leading global alternative investment firm with $45 billion of equity capital under management, is pleased to announce that one of its affiliates has acquired Aspire Pharma Limited (“Aspire” or the “Company”), a leading UK provider of niche generic and branded specialty pharmaceuticals, alongside its founder Graham Fraser-Pye. The financial terms of the transaction have not been disclosed. Aspire licenses and develops niche generic and specialty pharmaceutical products that offer innovative formulations, value for money for payors, and reliable supply arrangements in markets that are often underserved. The business holds leadership positions in urology, ophthalmology, CNS and dermatology, with a highly diversified portfolio of more than 250 products across multiple categories, including branded specialty products and unbranded niche generics. H.I.G., together with the management team, aims to continue Aspire’s strong track record of organic growth and

Swappable Announces Partnership with Esports T1's Dota 2 Team24.9.2021 14:34:00 EEST | Press release

Swappable, an NFT (Non-Fungible Token) interface for high-profile and exclusive digital collectibles, has announced its partnership with T1's Dota 2 team, the popular esports team for the upcoming International 10 - Dota 2 World Championship in Bucharest, Romania. T1 is not just an esports team but a pop culture phenomenon with millions of fans worldwide. The team embodies a blend of lifestyle, creativity and attitude, fresh from the source of Seoul & LA. As part of the collaboration, T1 will auction their first-ever NFTs (digital collectibles) on Swappable for T1’s Genesis Collection. With the first auction starting Friday September 24th, T1 will release a series of NFTs each possessing utility features such as special access to T1's Dota 2 team players and more. Visit Swappable for more information. “We are excited to partner with a leading organization in the esports industry. It is also a chance for T1 fans to pick the very first digital collectibles ever created by this legendary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom